Moving towards a reliable HIV incidence test - current status, resources available, future directions and challenges ahead

Imagem de Miniatura
Arquivos
art_MURPHY_Moving_towards_a_reliable_HIV_incidence_test_current_2017.PDF (402.22 KB)
Citações na Scopus
27
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
CAMBRIDGE UNIV PRESS
Autores
MURPHY, G.
PILCHER, C. D.
KEATING, S. M.
KASSANJEE, R.
FACENTE, S. N.
WELTE, A.
GREBE, E.
MARSON, K.
BUSCH, M. P.
DAILEY, P.
Citação
EPIDEMIOLOGY AND INFECTION, v.145, n.5, p.925-941, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
In 2011 the Incidence Assay Critical Path Working Group reviewed the current state of HIV incidence assays and helped to determine a critical path to the introduction of an HIV incidence assay. At that time the Consortium for Evaluation and Performance of HIV Incidence Assays (CEPHIA) was formed to spur progress and raise standards among assay developers, scientists and laboratories involved in HIV incidence measurement and to structure and conduct a direct independent comparative evaluation of the performance of 10 existing HIV incidence assays, to be considered singly and in combinations as recent infection test algorithms. In this paper we report on a new framework for HIV incidence assay evaluation that has emerged from this effort over the past 5 years, which includes a preliminary target product profile for an incidence assay, a consensus around key performance metrics along with analytical tools and deployment of a standardized approach for incidence assay evaluation. The specimen panels for this evaluation have been collected in large volumes, characterized using a novel approach for infection dating rules and assembled into panels designed to assess the impact of important sources of measurement error with incidence assays such as viral subtype, elite host control of viraemia and antiretroviral treatment. We present the specific rationale for several of these innovations, and discuss important resources for assay developers and researchers that have recently become available. Finally, we summarize the key remaining steps on the path to development and implementation of reliable assays for monitoring HIV incidence at a population level.
Palavras-chave
HIV/AIDS, incidence
URI
https://observatorio.fm.usp.br/handle/OPI/26192
Referências
  1. Andersson E, 2013, INFECT GENET EVOL, V18, P125, DOI 10.1016/j.meegid.2013.03.050
  2. Barin F, 2005, J CLIN MICROBIOL, V43, P4441, DOI 10.1128/JCM.43.9.4441-4447.2005
  3. BROOKMEYER R, 1995, AM J EPIDEMIOL, V141, P166, DOI 10.1093/oxfordjournals.aje.a117404
  4. Busch MP, 2010, AIDS, V24, P2763, DOI 10.1097/QAD.0b013e32833f1142
  5. Chawla A, 2007, J CLIN MICROBIOL, V45, P415, DOI 10.1128/JCM.01879-06
  6. Cousins MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051359
  7. Curtis KA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064201
  8. Duong YT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114947
  9. Duong YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033328
  10. Hargrove JW, 2008, AIDS, V22, P511, DOI 10.1097/QAD.0b013e3282f2a960
  11. Hargrove JW, 2009, AIDS, V23, P2061, DOI 10.1097/QAD.0b013e32832f3d8b
  12. Incidence Assay Critical Path Working Group, 2011, PLOS MED, V8, DOI 10.1371/JOURNAL.PMED.1001045
  13. Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42
  14. Kassanjee R, 2013, C RETR OPP INF ATL, P1056
  15. Kassanjee R, 2014, AIDS, V28, P2439, DOI 10.1097/QAD.0000000000000429
  16. Kassanjee R, 2012, EPIDEMIOLOGY, V23, P721, DOI 10.1097/EDE.0b013e3182576c07
  17. Keating SM, 2012, J CLIN MICROBIOL, V50, P3968, DOI 10.1128/JCM.01454-12
  18. Kimanga DO, 2014, JAIDS-J ACQ IMM DEF, V66, pS13, DOI 10.1097/QAI.0000000000000124
  19. Kothe D, 2003, JAIDS-J ACQ IMM DEF, V33, P625, DOI 10.1097/00126334-200308150-00012
  20. Laeyendecker O, 2013, J INFECT DIS, V207, P232, DOI 10.1093/infdis/jis659
  21. Li Hong, 2007, Int J Infect Dis, V11, P459, DOI 10.1016/j.ijid.2006.12.010
  22. Masciotra S, 2010, 17 C RETR OPP INF 16
  23. Mastro Timothy D, 2010, J HIV AIDS Surveill Epidemiol, V2, P1
  24. McDougal JS, 2009, AIDS, V23, P2064, DOI 10.1097/QAD.0b013e32832eff6e
  25. McWalter TA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007368
  26. Parekh BS, 2002, AIDS RES HUM RETROV, V18, P295, DOI 10.1089/088922202753472874
  27. Park SY, 2014, J VIROL, V88, P2977, DOI 10.1128/JVI.03128-13
  28. Rehle T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133255
  29. Schupbach J, 2007, PLOS MED, V4, P1921, DOI 10.1371/journal.pmed.0040343
  30. Shepherd SJ, 2015, J VIROL METHODS, V217, P42, DOI 10.1016/j.jviromet.2015.02.016
  31. Suligoi B, 2002, J CLIN MICROBIOL, V40, P4015, DOI 10.1128/JCM.40.11.4015-4020.2002
  32. Suligoi B, 2011, J CLIN MICROBIOL, V49, P2610, DOI 10.1128/JCM.02115-10
  33. UNAIDS/WHO, 2015, TECHN UPD HIV INC AS
  34. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance, 2011, US ASS REC INF EST H
  35. Wang R, 2009, JAIDS-J ACQ IMM DEF, V52, P538, DOI 10.1097/QAI.0b013e3181c080a7
  36. Welte A, 2009, AIDS, V23, P2062, DOI 10.1097/QAD.0b013e32832eff59
  37. Welte A, 2009, AIDS RES HUM RETROV, V25, P125, DOI 10.1089/aid.2008.0150
  38. Wilson KM, 2004, AIDS, V18, P2253, DOI 10.1097/00002030-200411190-00005

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - LIM/46
Artigos e Materiais de Revistas Científicas - ODS/03